Reuters logo
BRIEF-Sophiris Bio provides update on topsalysin mid-stage study
May 23, 2017 / 8:22 PM / 6 months ago

BRIEF-Sophiris Bio provides update on topsalysin mid-stage study

May 23 (Reuters) - Sophiris Bio Inc

* Sophiris bio provides update on phase 2b study of topsalysin in localized prostate cancer

* Sophiris bio inc - received regulatory clearance for diluent - medium in which topsalysin is diluted

* Sophiris bio inc - clinical sites can now begin dosing eligible patients in a phase 2b study in localized prostate cancer Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below